Flanders'Vaccine Elevator Pitch session: Connecting the Dots

One of the main goals of Flanders Vaccine is to bridge the gap between academic research and corporate development by creating awareness about early stage, pre-competitive novel technologies available in the Flanders Vaccine network. The Flanders Vaccine Elevator Pitch session offers a unique opportunity to connect academic researchers, entrepreneurs, TTO’s, business managers, scientific advisors and investors within the field of Vaccines and Immunotherapy. The following talented researchers and budding entrepreneurs will present their innovative project to an audience of potential partners and will benefit from the extensive scientific and business experience of the expert panel.

• BAXERNA: Next-Generation Bacterial mRNA Vaccines - Lyudmila Kovalchuke, Project Manager, VIB-UGent.
• High-sensitive immunopeptidomics uncovers actionable antigens paving the way for optimized vaccine development - Pieter-Paul Strybol, Business Developer, ImmuneSpec
• Resuscitating cell therapy for solid tumors: engineered CAR NK cells to overcome the immunosuppressive microenvironment -Jorrit De Waele, Post-doctoral researcher in Tumor immunology, University of Antwerp
• Novel Treatment of Urothelial Cancer of the Bladder in Dogs - Annelies Bogaerts, Chief Development Officer, Benno Therapeutics